PetVivo (NASDAQ:PETV – Get Free Report) is one of 143 publicly-traded companies in the “Medical Devices” industry, but how does it weigh in compared to its rivals? We will compare PetVivo to similar companies based on the strength of its earnings, risk, profitability, analyst recommendations, dividends, valuation and institutional ownership.
Profitability
This table compares PetVivo and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| PetVivo | -988.42% | -863.27% | -317.41% |
| PetVivo Competitors | -127.41% | -132.56% | -22.26% |
Valuation & Earnings
This table compares PetVivo and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| PetVivo | $920,000.00 | -$8.72 million | -2.19 |
| PetVivo Competitors | $437.09 million | $13.77 million | 90.42 |
Risk & Volatility
PetVivo has a beta of 1.99, indicating that its stock price is 99% more volatile than the S&P 500. Comparatively, PetVivo’s rivals have a beta of 0.84, indicating that their average stock price is 16% less volatile than the S&P 500.
Institutional and Insider Ownership
13.4% of PetVivo shares are owned by institutional investors. Comparatively, 29.0% of shares of all “Medical Devices” companies are owned by institutional investors. 24.9% of PetVivo shares are owned by insiders. Comparatively, 24.1% of shares of all “Medical Devices” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of recent recommendations and price targets for PetVivo and its rivals, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| PetVivo | 0 | 0 | 0 | 0 | N/A |
| PetVivo Competitors | 331 | 1241 | 1557 | 40 | 2.41 |
As a group, “Medical Devices” companies have a potential upside of 78.67%. Given PetVivo’s rivals higher possible upside, analysts plainly believe PetVivo has less favorable growth aspects than its rivals.
Summary
PetVivo rivals beat PetVivo on 8 of the 10 factors compared.
About PetVivo
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for PetVivo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetVivo and related companies with MarketBeat.com's FREE daily email newsletter.
